Biomarkers for amyotrophic lateral sclerosis.

Area of Science:

• Neuroscience
• Biomarker Research
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with a lengthy diagnostic process.
• Early diagnosis via biomarkers could improve patient management and outcomes.
• Current diagnostic timelines for ALS can take many months.

Purpose of the Study:

• To review the progress and challenges in biomarker discovery for ALS.
• To explore various technologies used in identifying potential ALS biomarkers.
• To highlight the significance of biomarkers for diagnosis, prognosis, and therapeutic development.

Main Methods:

• Review of proteomic, genomic, and metabolomic studies for ALS biomarker discovery.
• Analysis of genetic mutations associated with familial ALS.
• Examination of protein alterations in cerebrospinal fluid and blood of ALS patients.
• Evaluation of high-throughput technologies for biomarker panel identification.

Main Results:

• Identification of genetic mutations linked to familial ALS.
• Discovery of specific protein alterations in biological samples from ALS subjects.
• Development of proteomic and metabolic biomarker panels capable of distinguishing ALS from control groups.
• Progress in uncovering potential biomarkers for ALS diagnosis and progression monitoring.

Conclusions:

• Biomarker discovery is crucial for advancing ALS diagnosis and patient care.
• Proteomic, genomic, and metabolomic approaches are yielding promising results.
• Identified biomarkers can facilitate early diagnosis, monitor disease progression, and aid clinical trials.
• Continued research is essential to overcome remaining challenges in ALS biomarker development.